Del Colle Sara, Morello Fulvio, Rabbia Franco, Milan Alberto, Naso Diego, Puglisi Elisabetta, Mulatero Paolo, Veglio Franco
Division of Internal Medicine, Hypertension Unit, Department of Medicine and Experimental Oncology, University of Turin, Molinette Hospital, Turin, Italy.
J Cardiovasc Pharmacol. 2007 Nov;50(5):487-96. doi: 10.1097/FJC.0b013e318135446c.
Hypertension has been associated with several modifications in the function and regulation of the sympathetic nervous system (SNS). Although it is unclear whether this dysfunction is primary or secondary to the development of hypertension, these alterations are considered to play an important role in the evolution, maintenance, and development of hypertension and its target organ damage. Several pharmacological antihypertensive classes are currently available. The main drugs that have been clearly shown to affect SNS function are beta-blockers, alpha-blockers, and centrally acting drugs. On the contrary, the effects of ACE inhibitors (ACE-Is), AT1 receptor blockers (ARBs), calcium channel blockers (CCBs), and diuretics on SNS function remain controversial. These properties are pharmacologically and pathophysiologically relevant and should be considered in the choice of antihypertensive treatments and combination therapies in order to achieve, beyond optimal blood pressure control, a normalization of SNS physiology and the most effective prevention of target organ damage.
高血压与交感神经系统(SNS)功能及调节的多种改变有关。虽然尚不清楚这种功能障碍是原发性的还是高血压发展继发的,但这些改变被认为在高血压及其靶器官损害的进展、维持和发展中起重要作用。目前有几类药理降压药物。已明确显示会影响SNS功能的主要药物是β受体阻滞剂、α受体阻滞剂和中枢作用药物。相反,血管紧张素转换酶抑制剂(ACE-Is)、AT1受体阻滞剂(ARBs)、钙通道阻滞剂(CCBs)和利尿剂对SNS功能的影响仍存在争议。这些特性在药理和病理生理方面具有相关性,在选择降压治疗和联合治疗时应予以考虑,以便在实现最佳血压控制之外,使SNS生理功能正常化,并最有效地预防靶器官损害。